United States - English - NLM (National Library of Medicine)

novartis ophthalmics - levocabastine hydrochloride (unii: 124xma6yei) (levocabastine - unii:h68bp06s81) - suspension - 0.5 mg in 1 ml - livostin™ 0.05% (levocabastine hydrochloride ophthalmic suspension) is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis. this product is contraindicated in persons with known or suspected hypersensitivity to any of its components. it should not be used while soft contact lenses are being worn.

United States - English - NLM (National Library of Medicine)

allergan, inc. - levobunolol hydrochloride (unii: o90s49ldhh) (levobunolol - unii:g6317aoi7k) - levobunolol hydrochloride 5 mg in 1 ml - betagan ® ophthalmic solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension. betagan ® ophthalmic solution is contraindicated in those individuals with bronchial asthma, or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see warnings); sinus bradycardia; second and third degree atrioventricular block; overt cardiac failure (see warnings); cardiogenic shock; or hypersensitivity to any component of these products.

United States - English - NLM (National Library of Medicine)

sandoz inc - olopatadine hydrochloride (unii: 2xg66w44kf) (olopatadine - unii:d27v6190pm) - olopatadine hydrochloride ophthalmic solution 0.1% is indicated for the treatment of the signs and symptoms of allergic conjunctivitis. olopatadine hydrochloride ophthalmic solution 0.1% is contraindicated in persons with a known hypersensitivity to olopatadine hydrochloride or any components of olopatadine hydrochloride ophthalmic solution 0.1%.

United States - English - NLM (National Library of Medicine)

sandoz inc - carteolol hydrochloride (unii: 4797w6i0t4) (carteolol - unii:8nf31401xg) - carteolol hydrochloride ophthalmic solution 1% has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. it may be used alone or in combination with other intraocular pressure lowering medications. carteolol is contraindicated in those individuals with bronchial asthma or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease (see warnings ); sinus bradycardia; second- and third-degree atrioventricular block; overt cardiac failure (see warnings ); cardiogenic shock; or hypersensivity to any component of this product.

United States - English - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - olopatadine hydrochloride (unii: 2xg66w44kf) (olopatadine - unii:d27v6190pm) - indications and usage olopatadine hydrochloride ophthalmic solution, usp 0.1 % is indicated for the treatment of the signs and symptoms of allergic conjunctivitis. contraindications olopatadine hydrochloride ophthalmic solution, usp 0.1 % is contraindicated in persons with a known hypersensitivity to olopatadine hydrochloride or any components of olopatadine hydrochloride ophthalmic solution, usp 0.1%.

United States - English - NLM (National Library of Medicine)

paragon bioteck, inc. - phenylephrine hydrochloride (unii: 04ja59tnsj) (phenylephrine - unii:1ws297w6mv) - phenylephrine hydrochloride ophthalmic solution, usp 2.5% and 10% is indicated to dilate the pupil. phenylephrine hydrochloride ophthalmic solution, usp 10% is contraindicated in patients with hypertension, or thyrotoxicosis. phenylephrine hydrochloride ophthalmic solution, usp 2.5% should be used in these patients. phenylephrine hydrochloride ophthalmic solution, usp 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. phenylephrine hydrochloride ophthalmic solution, usp 2.5% should be used in these patients [see dosage and administration ( 2.2)]. animal reproduction studies have not been conducted with topical phenylephrine. it is also not known whether phenylephrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. phenylephrine hydrochloride ophthalmic solution, usp 2.5% and 10% should be given to a pregnant woman only if clearly needed. it is not known whether this drug is excrete

United States - English - NLM (National Library of Medicine)

proficient rx lp - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin hydrochloride ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: corneal ulcers: pseudomonas aeruginosa serratia marcescens* staphylococcus aureus staphylococcus epidermidis streptococcus pneumoniae streptococcus (viridans group)* conjunctivitis: haemophilus influenzae staphylococcus aureus staphylococcus epidermidis streptococcus pneumoniae *efficacy for this organism was studied in fewer than 10 infections. a history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. a history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin. safety and effectiveness in pediatric patients below the age of 1 year have not been established. although ciprofloxacin and other quinolones cause arthropathy in immature animals after oral administration, topical ocular administration of ciprofloxacin to immature

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - olopatadine hydrochloride (unii: 2xg66w44kf) (olopatadine - unii:d27v6190pm) - olopatadine hydrochloride ophthalmic solution usp 0.1 % is indicated for the treatment of the signs and symptoms of allergic conjunctivitis. olopatadine hydrochloride ophthalmic solution 0.1 % is contraindicated in persons with a known hypersensitivity to olopatadine hydrochloride or any components of olopatadine hydrochloride ophthalmic solution.

United States - English - NLM (National Library of Medicine)

leading pharma, llc - dorzolamide hydrochloride (unii: qzo5366ew7) (dorzolamide - unii:9jdx055tw1) - dorzolamide hydrochloride ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. dorzolamide hydrochloride ophthalmic solution is contraindicated in patients who are hypersensitive to any component of this product [see warnings and precautions (5.1) ]. teratogenic effects. developmental toxicity studies with dorzolamide hydrochloride in rabbits at oral doses of ≥ 2.5 mg/kg/day revealed malformations of the vertebral bodies. these malformations occurred at doses that caused metabolic acidosis with decreased body weight gain in dams and decreased fetal weights. no treatment-related malformations were seen at 1 mg/kg/day. these doses represent estimated plasma cmax levels in rabbits, 37 and 15 times higher than the lower limit of detection in human plasma following ocular administration, respectively. there are no adequate and well-controlled studies in pregnant women. dorzolamide hydrochloride ophthalmic solution should b

United States - English - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - ciprofloxacin hydrochloride (unii: 4ba73m5e37) (ciprofloxacin - unii:5e8k9i0o4u) - ciprofloxacin hydrochloride ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: corneal ulcers: pseudomonas aeruginosa serratia marcescens* staphylococcus aureus staphylococcus epidermidis streptococcus pneumoniae streptococcus (viridans group)* conjunctivitis: haemophilus influenzae staphylococcus aureus staphylococcus epidermidis streptococcus pneumoniae *efficacy for this organism was studied in fewer than 10 infections. a history of hypersensitivity to ciprofloxacin or any other component of the medication is a contraindication to its use. a history of hypersensitivity to other quinolones may also contraindicate the use of ciprofloxacin. safety and effectiveness in pediatric patients below the age of 1 year have not been established. although ciprofloxacin and other quinolones cause arthropathy in immature animals after oral administration, topical ocular administration of ciprofloxacin to immature